Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC.
10.19746/j.cnki.issn.1009-2137.2020.03.029
- Author:
Xi-Feng WU
1
;
Tan-Tan LI
1
;
Ling SUN
1
;
Li-Juan WANG
1
;
Xue-Hong RAN
2
Author Information
1. Department of Hematology, Jinan Municipal People's Hospital, Jinan 271100, Shandong Province, China.
2. Department of Hematology, Weifang Municipal People's Hospital, Weifang 261042, Shandong Province, China,E-mail: ggtgyx1@126.com.
- Publication Type:Journal Article
- MeSH:
Anemia, Refractory, with Excess of Blasts;
Antineoplastic Combined Chemotherapy Protocols;
Cytarabine;
Decitabine;
Granulocyte Colony-Stimulating Factor;
Humans;
Leukemia, Myeloid, Acute;
Myelodysplastic Syndromes;
Retrospective Studies;
Treatment Outcome
- From:
Journal of Experimental Hematology
2020;28(3):894-898
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the influence of conventional CAG regimen and decitabine + decreased dose CAG (D+dCAG) regimen on the clinical efficacy and safety of patients with MDS-RAEB/AML-MRC.
METHODS:The clinical data of 67 patients with MDS-RAEB/AML-MRC hospitalized in our hospital from March 2012 to July 2017 were analyzed retrospectively. According to chemotherapecctic regimens, 76 patients were divided into 2 groups: 37 patients treated with conventional CAG regimen were enrolled in control group, 30 patients treated with decitabine + decreased dose CAG regimen were enrolled in D+dCAG group. The complete remission (CR) rate, overall remission rate (ORR), OS and PFS time and incidence of adverse reactions in 2 groups were compared.
RESULTS:The CR in D+dCAG group was significantly higher than that in control group (P＜0.05). ORR was not significanly different between 2 groups (P＞0.05). There was no significant difference in the cumulative OS rate between 2 groups (P＞0.05). There was no significant difference in the cumulative OS rate and PFS rate in nonimplantation between 2 groups (P＞0.05). The incidence of adverse reactions of hematological system, pulmonary infection, skin and soft tissue infection, agranulocytosic fever and mycotic infection was not significanly different between 2 groups (P＞0.05). The duration of granulocyte deficiency and platelet count less than 20×10/L were not significanly different between 2 groups (P＞0.05).
CONCLUSION:Compared with conventional CAG regimen, decitabine + decreased dose CAG regimen in the treatment of patients with MDS-RAEB/AML-MRC can efficiently improve the remission effects and showed the well overall safety, but can not increase the survival rate.
